View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
April 15, 2020

Covid-19: Healthcare daily update

By Paul Dennis

Protease inhibitors for Covid-19: could disease severity have impacted results?
In early January, when the coronavirus outbreak was being watched as a developing global threat, AbbVie was one of the first companies to donate its HIV protease inhibitors combination therapy Aluvia (lopinavir / ritonavir), also known as Kaletra, to help China treat patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.

Covid-19 pandemic interferes with ongoing clinical developments in female health
The female health space is facing pauses in drug development and certain treatments due to the Covid-19 pandemic. On 23 March, ObsEva provided an update regarding the impact of Covid-19 on the company’s clinical development programs.

The company stated that patient screening and randomisation in its ongoing Phase III trials of its oral GnRH receptor antagonist linzagolix for endometriosis-associated pain, EDELWEISS 2 and EDELWEISS 3, are voluntarily being paused until further notice.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU